All 13 Provinces and Territories have been working together to achieve greater value for brand name and generic drugs for publicly funded drug programs. These initiatives, formerly known as the Pan-Canadian Pricing Alliance and the Generic Value Price Initiative, are now referenced collectively as the pan-Canadian Pharmaceutical Alliance (pCPA). Nova Scotia is currently co-leading with Saskatchewan on the generic drugs initiative and with Ontario on the brand name drugs initiative.

Federal Drug Plans are now participating in the pCPA. We look forward to their involvement in both Brand and Generic efforts by the pCPA.

An Office with dedicated staff to support the work of the pCPA is being hosted in Ontario. The decision to establish an Office of the pCPA (Office) was informed by the work completed by IBM Canada Ltd based on a review of international best practices and broad consultation with both internal and external stakeholders. The report is titled “Pan Canadian Drugs Negotiation Report” (Report) and can be found at the bottom of this page.

Following significant work to formalize its structure and launch, the new Office is operational as of September 2015 – located in Toronto at 900 Bay Street on the 2nd floor of the Hepburn Block. The full Office team is now in place:

Imran Ali (Senior Manager)
Anchalee Srisombun (Senior Negotiator)
Sang Mi Lee (Senior Pharmacist)
Karleen Jung (Senior Economist)
Nessa Podkoscielny (Negotiations Consultant)

The transition team (ON, NS and SK) have been leading the development of guiding principles and phased implementation of the mandate to ensure the Office achieves its mission.

Consistent with our commitment to keep the sector and our various stakeholder groups apprised of progress, the co-lead jurisdictions hosted two stakeholder sessions on June 16, 2015 one for patient and caregiver groups and the other for the pharmaceutical sector. These sessions were well attended and provided an opportunity for both an update to be provided and for input into the ongoing work.

Effective April 1, 2018, nearly 70 of the most commonly prescribed drugs in Canada are priced at either 10% or 18% of the equivalent brand name product.

10% Oral Solid

  • Amlodipine
  • Atorvastatin
  • Citalopram
  • Clopidogrel
  • Donepezil
  • Ezetimibe
  • Gabapentin
  • Metformin
  • Olanzapine
  • Olanzapine ODT
  • Omeprazole
  • Pantoprazole
  • Quetiapine
  • Rabeprazole EC
  • Ramipril
  • Ranitidine
  • Rosuvastatin
  • Simvastatin
  • Venlafaxine XR
  • Zopiclone

18% Oral Solid

  • Alendronate
  • Almotriptan
  • Amiodarone
  • Anastrozole
  • Atenolol
  • Atomoxetine
  • Azithromycin
  • Bicalutamide
  • Bisoprolol
  • Candesartan
  • Candesartan HCTZ
  • Carvedilol
  • Celecoxib
  • Ciprofloxacin
  • Clonazepam
  • Cyclobenzaprine
  • Domperidone
  • Dutasteride
  • Eletriptan
  • Escitalopram
  • Famciclovir
  • Finasteride
  • Fluoxetine
  • Imatinib
  • Irbesartan
  • Irbesartan HCTZ
  • Lamotrigine
  • Levetiracetam
  • Memantine
  • Minocycline
  • Montelukast
  • Mycophenolate
  • Paroxetine
  • Pramipexole
  • Pravastatin
  • Pregabalin
  • Risedronate
  • Risperidone
  • Sertraline
  • Solifenacin
  • Sumatriptan DF
  • Telmisartan
  • Telmisartan HCTZ
  • Terbinafine
  • Topiramate
  • Valacyclovir
  • Valsartan
  • Valsartan HCTZ